1 min read
Add as a preferred source on Google

Merck Ends Nemtabrutinib Development After Phase 3 Trial Review

A data monitoring committee raised concerns that the drug’s potential benefits might not outweigh its risks.

A white capsule rests alone in an empty clinical trial tray / TokenPost.ai (mono)
A white capsule rests alone in an empty clinical trial tray / TokenPost.ai (mono)

During a Phase 3 trial review, a data monitoring committee raised concerns that nemtabrutinib’s potential benefits did not offset its risks; Merck & Co. has ended development of the drug.

Nemtabrutinib is an oral, non-covalent inhibitor of Bruton's tyrosine kinase (BTK).

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…